Health · 1 sources covering this

STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states

Sandoz agreed to pay $478.5 million to settle allegations that the company engaged in a conspiracy to artificially inflate and manipulate prices.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states
Sandoz agreed to pay $478.5 million to settle allegations that the company engaged in a conspiracy to artificially inflate and manipulate prices.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/8cca18e3ccae50c4b8afb574c9d87163345cb401"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states"></iframe>

STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states

How 1 sources are covering this

STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states

More from Health

STAT+: Is there a pharma mega-merger in the making?

STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more

New York’s assisted-dying law moves forward

STAT+: BioNTech names Guido Oelkers its new CEO

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states

More from Health

STAT+: Is there a pharma mega-merger in the making?

STAT+: Pharmalittle: We&#8217;re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more

New York’s assisted-dying law moves forward

STAT+: BioNTech names Guido Oelkers its new CEO

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more